MIST Milestone Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1408443 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-68.7%
TTM EPS YoY6.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,370.6%
ROA-78.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets103.8%
Debt / equity—
Current ratio6.27x
Interest coverage-7.62x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-16.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.96M | $559,000 | $238,000 | — | $0 | $0 | $0 | — |
| Cost of revenue | $325,000 | $32,000 | $14,000 | — | $0 | $0 | $0 | — |
| Gross profit | $2.64M | $527,000 | $224,000 | — | $0 | $0 | $0 | — |
| R&D expense | $3.46M | $3.51M | $3.25M | $5.52M | $3.94M | $3.67M | $4.98M | $3.94M |
| SG&A expense | $24.23M | $22.65M | $4.82M | $5.08M | $7.89M | $8.86M | $5.17M | $4.00M |
| Operating income | -$25.05M | -$25.63M | -$23.66M | -$17.26M | -$11.83M | -$12.53M | -$20.52M | -$12.35M |
| Interest expense | $2.18M | $4.72M | $4.13M | $985,000 | $967,000 | $951,000 | $935,000 | $919,000 |
| Net income | -$25.80M | -$28.61M | -$26.07M | -$17.41M | -$11.92M | -$12.97M | -$20.76M | -$12.36M |
| EBITDA | -$25.00M | -$25.57M | -$23.61M | -$17.22M | -$11.80M | -$12.50M | -$20.50M | -$12.32M |
| EPS (basic) | -0.18 | -0.21 | -0.20 | — | -0.12 | -0.20 | -0.31 | — |
| EPS (diluted) | -0.18 | -0.21 | -0.20 | — | -0.12 | -0.20 | -0.31 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $144.47M | $169.73M | $71.32M | $73.05M | $46.69M | $42.50M | $45.09M | $25.31M |
| Short-term investments | $882,000 | $881,000 | $112.90M | $32.91M | $35.90M | $918,000 | $10.87M | $44.38M |
| Receivables | $3.93M | $2.72M | $1.60M | — | — | — | — | — |
| Inventory | $6.68M | $4.72M | $1.83M | $648,000 | — | — | — | — |
| Current assets | $161.60M | $180.33M | $192.25M | $111.92M | $86.67M | $46.17M | $60.48M | $73.93M |
| PP&E, net | $416,000 | $469,000 | $500,000 | $511,000 | $136,000 | $159,000 | $176,000 | $197,000 |
| Total assets | $162.69M | $181.62M | $193.73M | $113.56M | $87.75M | $47.42M | $61.88M | $75.50M |
| Current liabilities | $25.78M | $22.18M | $20.94M | $13.98M | $10.52M | $9.28M | $12.96M | $8.13M |
| Long-term debt | $60.24M | $59.21M | $58.19M | $57.19M | $56.21M | $55.24M | $54.29M | $53.35M |
| Total debt | $60.24M | $59.21M | $58.19M | $57.19M | $56.21M | $55.24M | $54.29M | $53.35M |
| Total liabilities | $168.91M | $163.41M | $157.69M | $71.79M | $67.25M | $65.16M | $68.01M | $62.35M |
| Shareholders' equity | -$6.22M | $18.22M | $36.05M | $41.77M | $20.50M | -$17.75M | -$6.12M | $13.15M |
| Net debt | -$84.23M | -$110.52M | -$13.12M | -$15.86M | $9.52M | $12.74M | $9.20M | $28.04M |
| Shares outstanding | 124.50M | 124.50M | 117.79M | 106.24M | 85.17M | 53.49M | 53.46M | 53.35M |
| Cash flow statement | ||||||||
| Operating cash flow | -$25.24M | -$22.71M | -$16.05M | -$12.78M | -$9.75M | -$12.57M | -$13.95M | -$6.84M |
| Capital expenditure | $4,000 | $26,000 | $45,000 | $283,000 | $2,000 | $11,000 | $6,000 | $22,000 |
| Free cash flow | -$25.25M | -$22.74M | -$16.10M | -$13.06M | -$9.75M | -$12.58M | -$13.96M | -$6.87M |
| Investing cash flow | -$5,000 | $111.99M | -$80.03M | $2.70M | -$34.98M | $9.94M | $33.58M | $19.33M |
| Financing cash flow | -$9,000 | $9.13M | $94.35M | $36.43M | $48.92M | $36,000 | $140,000 | $24,000 |
| Depreciation & amortization | $57,000 | $57,000 | $56,000 | $34,000 | $25,000 | $28,000 | $27,000 | $26,000 |
| Stock-based compensation | $1.36M | $1.34M | $1.28M | $3.55M | $1.25M | $1.31M | $1.35M | $1.47M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.